2016
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro
Bellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecologic Oncology 2016, 144: 146-152. PMID: 27894751, PMCID: PMC5183545, DOI: 10.1016/j.ygyno.2016.11.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsCarboplatinCarcinomaCD4 Lymphocyte CountCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell SurvivalDisease-Free SurvivalDNA Polymerase IIDrug Resistance, NeoplasmEndometrial NeoplasmsFemaleHumansMicrosatellite InstabilityMiddle AgedMutationPoly-ADP-Ribose Binding ProteinsTumor Cells, CulturedConceptsBetter prognosisTumor cell linesInfiltration of CD4Number of CD4Platinum-based chemotherapyT lymphocyte infiltrationPD-1 receptorCell linesLow metastatic capabilityPOLE-mutated tumorsWild-type ECsEC cell linesLymphocyte infiltrationFavorable prognosisPD-1EC patientsType tumorsEnhanced immunogenicityT lymphocytesMolecular subtypesTumors correlatesChemotherapyMetastatic capabilityPrognosisTumors
2014
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
Schwab CL, Bellone S, English DP, Roque DM, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. British Journal Of Cancer 2014, 111: 1750-1756. PMID: 25268372, PMCID: PMC4453741, DOI: 10.1038/bjc.2014.519.Peer-Reviewed Original ResearchMeSH KeywordsAdultAfatinibAgedAged, 80 and overAnimalsApoptosisCell CycleCell ProliferationCystadenocarcinoma, SerousEndometrial NeoplasmsFemaleHumansImmunoenzyme TechniquesIn Situ Hybridization, FluorescenceIn Vitro TechniquesMiceMice, SCIDMiddle AgedPhosphorylationQuinazolinesReceptor, ErbB-2Signal TransductionTumor Cells, CulturedUterine NeoplasmsXenograft Model Antitumor AssaysConceptsUterine serous carcinomaUSC cell linesHER2/neu gene amplificationNeu gene amplificationAfatinib exposureOverall survivalCell linesHER2/neu amplificationEfficacy of afatinibPrimary USC cell linesGrowth of HER2Treatment of HER2Serous endometrial cancerErbB tyrosine kinase inhibitorsHER2/neuTyrosine kinase inhibitorsGene amplificationFlow cytometry assayCell cycle distributionUSC xenograftsEndometrial cancerSerous carcinomaUterine cancerAggressive formTumor xenografts
2011
Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation
Magaldi TG, Almstead LL, Bellone S, Prevatt EG, Santin AD, DiMaio D. Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation. Virology 2011, 422: 114-124. PMID: 22056390, PMCID: PMC3229657, DOI: 10.1016/j.virol.2011.10.012.Peer-Reviewed Original ResearchConceptsCervical carcinoma cellsCervical cancer cellsHuman papillomavirus E6Human cervical carcinoma cellsCarcinoma cellsPrimary cervical cancer cellsCancer cellsPapillomavirus E6Cervical carcinoma cell linesE2 proteinHuman cervical cancer cellsCarcinoma cell linesE7 expressionE7 oncogenesLow passage numberSerum-free conditionsCell surface receptorsSV40 infectionTumor suppressor pathwayCell linesPrimary cellsViral vectorsE6Suppressor pathwayPassage number
2010
Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer
Cocco E, Casagrande F, Bellone S, Richter CE, Bellone M, Todeschini P, Holmberg JC, Fu HH, Montagna MK, Mor G, Schwartz PE, Arin-Silasi D, Azoudi M, Rutherford TJ, Abu-Khalaf M, Pecorelli S, Santin AD. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC Cancer 2010, 10: 349. PMID: 20598131, PMCID: PMC2908101, DOI: 10.1186/1471-2407-10-349.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma, Clear CellAnimalsCarcinoma, PapillaryCarcinoma, Squamous CellChlorocebus aethiopsClaudin-3Claudin-4Clostridium perfringensCystadenocarcinoma, SerousDrug Resistance, NeoplasmEnterotoxinsFemaleFibroblastsFlow CytometryHumansMembrane ProteinsMiceMice, SCIDOvarian NeoplasmsPeptide FragmentsReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSpheroids, CellularTissue DistributionTransplantation, HeterologousTumor Cells, CulturedUterine Cervical NeoplasmsVero CellsConceptsChemotherapy-resistant ovarian cancerClostridium perfringens enterotoxinOvarian cancerOvarian carcinoma cell linesClaudin-3Carcinoma cell linesNovel tumor-homing peptideCarboxy-terminal fragmentTumor cellsResistant ovarian cancer cell linesCell linesNew diagnostic tracersCPE peptideOvarian cancer cell linesResistant ovarian cancer cellsResistant ovarian carcinomaHuman ovarian cancerRelevant animal modelsOvarian tumor cellsOvarian cancer cellsChemotherapy-resistant ovarian cancer cellsHuman epithelial tumorsTime-dependent internalizationCancer cell linesBio-distribution studies
2009
Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer: Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy
Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer: Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy. International Journal Of Gynecological Cancer 2009, 19: 860-866. PMID: 19574774, DOI: 10.1111/igc.0b013e3181a8331f.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdenocarcinoma, MucinousAdultAntigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsBlotting, WesternCarcinoma, PapillaryCell Adhesion MoleculesChemotherapy, AdjuvantCystadenocarcinoma, SerousDrug Resistance, NeoplasmEndometrial NeoplasmsEpithelial Cell Adhesion MoleculeFemaleFlow CytometryHumansImmunoenzyme TechniquesMiddle AgedNeoplasm Recurrence, LocalOrganoplatinum CompoundsOvarian NeoplasmsOvaryPrognosisRetrospective StudiesReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSurvival RateTreatment OutcomeTumor Cells, CulturedConceptsRecurrent epithelial ovarian carcinomaEpithelial ovarian carcinomaNormal ovarian tissuesOvarian carcinoma cell linesOvarian carcinomaEpithelial cell adhesion moleculeEp-CAMCarcinoma cell linesCell adhesion moleculeOvarian tissueChemotherapy-resistant epithelial ovarian cancerFlow cytometryCell linesAdhesion moleculesEp-CAM overexpressionStandard treatment modalityCell adhesion molecule expressionOvarian carcinoma patientsEpithelial ovarian cancerPrimary ovarian carcinomasAdhesion molecule expressionSurface expressionAntibody-mediated therapyHuman monoclonal antibodyEpithelial cell adhesion molecule (EpCAM) expressionSerum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer
Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Casagrande F, Buza N, Tavassoli FA, Siegel ER, Visintin I, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. British Journal Of Cancer 2009, 101: 335-341. PMID: 19536090, PMCID: PMC2720219, DOI: 10.1038/sj.bjc.6605129.Peer-Reviewed Original ResearchConceptsUterine serous papillary carcinomaSerum amyloid AUSPC patientsBenign diseaseSAA concentrationsNovel biomarkersPrimary USPC cell linesUterine serous papillary cancerSerum SAALiver-secreted proteinsNormal healthy femalesUSPC cell linesEarly disease recurrenceSerous papillary carcinomaNormal endometrial tissuesExpression levelsProtein expression levelsEndometrial cancerAggressive variantHealthy womenEndometrial tissuePapillary cancerSerum biomarkersAmyloid AHealthy group
2008
Claudin‐7 expression in human epithelial ovarian cancer
TASSI RA, BIGNOTTI E, FALCHETTI M, RAVANINI M, CALZA S, RAVAGGI A, BANDIERA E, FACCHETTI F, PECORELLI S, SANTIN AD. Claudin‐7 expression in human epithelial ovarian cancer. International Journal Of Gynecological Cancer 2008, 18: 1262-1271. PMID: 18298564, DOI: 10.1111/j.1525-1438.2008.01194.x.Peer-Reviewed Original ResearchConceptsEpithelial ovarian carcinomaHistologic typeClaudin-7 expressionClaudin-7Ovarian carcinomaOvarian cancerPeritoneal cavityEOC cellsMetastatic epithelial ovarian carcinomaHuman epithelial ovarian cancerCLDN-7 expressionMain histologic typesEpithelial ovarian cancerProtein levelsGrade of differentiationReverse transcription-polymerase chain reactionTranscription-polymerase chain reactionTight junction proteinsNovel diagnostic markerEpithelium cell lineSingle neoplastic cellsHuman normal tissuesPleural effusionPathologic stageInflammatory cells
2007
Overexpression of claudin‐3 and claudin‐4 receptors in uterine serous papillary carcinoma
Santin AD, Bellone S, Marizzoni M, Palmieri M, Siegel ER, McKenney JK, Hennings L, Comper F, Bandiera E, Pecorelli S. Overexpression of claudin‐3 and claudin‐4 receptors in uterine serous papillary carcinoma. Cancer 2007, 109: 1312-1322. PMID: 17326053, DOI: 10.1002/cncr.22536.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnimalsClaudin-3Claudin-4Clostridium perfringensCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousDrug Resistance, NeoplasmEnterotoxinsFemaleGene ExpressionHumansInjections, IntraperitonealMembrane ProteinsMiceMice, SCIDMiddle AgedReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTumor Cells, CulturedUp-RegulationUterine Cervical NeoplasmsXenograft Model Antitumor AssaysConceptsUterine serous papillary carcinomaClaudin-4 receptorsUSPC cell linesSerous papillary carcinomaClaudin-3Endometrial cancerPapillary carcinomaClaudin-4 protein expressionChemotherapy-resistant variantsCytotoxic Clostridium perfringensSublethal intraperitoneal injectionsReverse transcriptase-polymerase chain reactionQuantitative reverse transcriptase-polymerase chain reactionTumor cell necrosisSCID mouse xenograftsType-specific therapiesDose-dependent cytotoxic effectCell linesTight junction proteinsControl tissue samplesHigh-affinity receptorAggressive variantTumor disappearanceIntraperitoneal injectionPolymerase chain reaction
2006
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy
Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, Falchetti M, Odicino FE, Pecorelli S, Santin AD. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy. Gynecologic Oncology 2006, 103: 405-416. PMID: 16725184, DOI: 10.1016/j.ygyno.2006.03.056.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBiopsyClaudin-3Claudin-4Cystadenocarcinoma, SerousEpithelial CellsFemaleGene Expression ProfilingHumansImmunohistochemistryKallikreinsMammaglobin AMembrane ProteinsMiddle AgedNeoplasm ProteinsOvarian NeoplasmsReverse Transcriptase Polymerase Chain ReactionTumor Cells, CulturedUteroglobinConceptsGene expression profilesGene expression profilingExpression profilingExpression profilesGenetic fingerprintsDifferential gene expression profilesNovel molecular biomarkersGene expression productsOvarian serous papillary carcinomaGene expression dataHuman genesGene expressionMolecular biomarkersOligonucleotide microarraysExpression productsPrimary tumor cell culturesExpression dataQuantitative RT-PCREnterotoxin receptorGenesMicroarray dataKallikrein 6Ovarian serous carcinomaProtein levelsMammaglobin 2
2005
Human Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer
Santin AD, Diamandis EP, Bellone S, Soosaipillai A, Cane S, Palmieri M, Burnett A, Roman JJ, Pecorelli S. Human Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer. Clinical Cancer Research 2005, 11: 3320-3325. PMID: 15867230, DOI: 10.1158/1078-0432.ccr-04-2528.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCarcinoma, EndometrioidCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousEndometrial NeoplasmsEnzyme-Linked Immunosorbent AssayFemaleGene Expression Regulation, NeoplasticHumansKallikreinsMiddle AgedReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTumor Cells, CulturedUterine NeoplasmsConceptsUterine serous papillary carcinomaSerous papillary carcinomaEndometrioid carcinomaUSPC patientsBenign diseasePapillary carcinomaNovel biomarkersPrimary USPC cell linesUterine serous papillary cancerOvarian serous papillary carcinomaEndometrioid carcinoma patientsNormal healthy femalesUSPC cell linesEarly disease recurrenceNormal endometrial cellsPotential serum biomarkersPrimary endometrioid carcinomaNew Potential Serum BiomarkerExpression levelsGene expression levelsHK6 proteinEndometrial biopsyCarcinoma patientsDisease recurrenceEndometrial cancerGene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
Santin AD, Zhan F, Cane' S, Bellone S, Palmieri M, Thomas M, Burnett A, Roman JJ, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. British Journal Of Cancer 2005, 92: 1561-1573. PMID: 15785748, PMCID: PMC2362016, DOI: 10.1038/sj.bjc.6602480.Peer-Reviewed Original ResearchConceptsUterine serous papillary cancerNormal endometrial cellsEndometrial cancerAggressive variantClaudin-4Normal endometrial epithelial cellsUterine serous papillary carcinomaAdhesion moleculesNovel therapeutic markerCommon gynecologic tumorsSerous papillary carcinomaParaffin-embedded specimensEndometrial epithelial cellsL1 cell adhesion moleculeType-specific therapiesRas homolog gene familyQuantitative RT-PCRScalar dosesGynecologic tumorsPapillary cancerEndometrial cellsInterleukin-6Cell adhesion moleculeNovel molecular markersPapillary carcinoma
2003
The novel serine protease tumor‐associated differentially expressed gene–15 (matriptase/MT‐SP1) is highly overexpressed in cervical carcinoma
Santin AD, Cane' S, Bellone S, Bignotti E, Palmieri M, De Las Casas LE, Anfossi S, Roman JJ, O'Brien T, Pecorelli S. The novel serine protease tumor‐associated differentially expressed gene–15 (matriptase/MT‐SP1) is highly overexpressed in cervical carcinoma. Cancer 2003, 98: 1898-1904. PMID: 14584072, DOI: 10.1002/cncr.11753.Peer-Reviewed Original ResearchSelection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy
Bellone S, Palmieri M, Gokden M, Joshua J, Roman JJ, Pecorelli S, Cannon MJ, Santin AD. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecologic Oncology 2003, 91: 231-240. PMID: 14529687, DOI: 10.1016/s0090-8258(03)00460-8.Peer-Reviewed Original ResearchConceptsAntibody-dependent cellular cytotoxicityEarly-stage cervical cancerStage cervical cancerCervical cancer cell linesCancer cell linesCervical cancerPrimary cell linesNeu expressionPrimary cervical cancer cell linesCell linesHER-2/neu expressionSite of recurrenceInhibition of proliferationEffector cellsMetastatic lesionsIL-2Primary treatmentTumor biopsiesCellular cytotoxicityHumanized mAbOriginal tumorRecurrent sitesLow dosesFlow cytometryLow expressionRestoration of Tumor-Specific HLA Class I Restricted Cytotoxicity in Tumor Infiltrating Lymphocytes of Advanced Breast Cancer Patients by in vitro Stimulation with Tumor Antigen-Pulsed Autologous Dendritic Cells
Kass R, Bellone S, Palmieri M, Canè S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD. Restoration of Tumor-Specific HLA Class I Restricted Cytotoxicity in Tumor Infiltrating Lymphocytes of Advanced Breast Cancer Patients by in vitro Stimulation with Tumor Antigen-Pulsed Autologous Dendritic Cells. Breast Cancer Research And Treatment 2003, 80: 275-285. PMID: 14503800, DOI: 10.1023/a:1024938215782.Peer-Reviewed Original ResearchConceptsPeripheral blood lymphocytesCytotoxic T lymphocytesTumor-specific cytotoxic T lymphocytesTumor-specific lytic activityAdvanced breast cancer patientsBreast cancer patientsCancer patientsInterleukin-2Breast cancerAnti-HLA class I mAbsNK-sensitive cell line K562Tumor-specific T-cell responsesChemotherapy-resistant breast cancerAdoptive T-cell immunotherapyAutologous dendritic cellsTh1 cytokine biasAutologous tumor cellsResistant breast cancerT cell responsesTumor-Infiltrating LymphocytesDendritic cell stimulationT cell populationsT-cell immunotherapyPotential of tumorHLA class IIn vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells11Supported in part by grants from the Arkansas Breast Cancer Research Program, the Arkansas Special Population Network (A-SPAN), and the Camillo Golgi Foundation, Brescia, Italy (to A.S.).
Kass R, Agha J, Bellone S, Palmieri M, Canè S, Bignotti E, Henry-Tillman R, Hutchins L, Cannon MJ, Klimberg S, Santin AD. In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells11Supported in part by grants from the Arkansas Breast Cancer Research Program, the Arkansas Special Population Network (A-SPAN), and the Camillo Golgi Foundation, Brescia, Italy (to A.S.). Journal Of Surgical Research 2003, 112: 189-197. PMID: 12888337, DOI: 10.1016/s0022-4804(03)00147-1.Peer-Reviewed Original ResearchConceptsAutologous tumor cellsAdvanced breast cancerHLA class IAntigen-pulsed dendritic cellsIntracellular cytokine expressionDendritic cellsBreast cancerFlow cytometric analysisTumor cellsCytokine expressionClass IT lymphocytesAutologous Epstein-Barr virus-transformed lymphoblastoid cell linesTumor antigen-pulsed dendritic cellsTumor lysate-pulsed dendritic cellsLysate-pulsed dendritic cellsPowerful antigen-presenting cellsTwo-color flow cytometric analysisCytometric analysisPeripheral blood mononuclear cellsSurface markersVirus-transformed lymphoblastoid cell linesEpstein-Barr virus-transformed lymphoblastoid cell linesColor flow cytometric analysisBreast Cancer Research Program
2002
Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP. Overexpression of HER-2/neu in uterine serous papillary cancer. Clinical Cancer Research 2002, 8: 1271-9. PMID: 12006548.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsBreast NeoplasmsCell DivisionCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousFemaleFlow CytometryHumansImmunohistochemistryInterleukin-2Killer Cells, NaturalMiddle AgedNeoplasm StagingOvarian NeoplasmsReceptor, ErbB-2RituximabTrastuzumabTumor Cells, CulturedUterine NeoplasmsConceptsUterine serous papillary carcinomaAntibody-dependent cellular cytotoxicityUSPC cell linesIntensity of expressionOvarian cancerPrimary USPC cell linesUterine serous papillary cancerCell linesFlow cytometryHigh-grade ovarian cancerOvarian cancer cell linesSerous papillary carcinomaCell proliferationComplement-dependent cytotoxicityComplement-mediated cytotoxicityAttractive therapeutic strategyHuman serum IgGCancer cell linesEndometrial cancerNatural killerAggressive variantEffector cellsSerum IgGPapillary cancerIL-2Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer.
Santin AD, Bellone S, Underwood LJ, O'Brien TJ, Ravaggi A, Pecorelli S, Cannon MJ. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer. Minerva Obstetrics And Gynecology 2002, 54: 133-44. PMID: 12032451.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntigens, NeoplasmCancer VaccinesChildClinical Trials as TopicCombined Modality TherapyDendritic CellsFemaleGPI-Linked ProteinsHumansImmunohistochemistryImmunotherapyKallikreinsMatrix Metalloproteinase 7Membrane ProteinsNeoplasm MetastasisOvarian NeoplasmsSerine EndopeptidasesT-Lymphocytes, CytotoxicTumor Cells, CulturedConceptsTumor antigensOvarian cancerChemotherapy-resistant ovarian cancerOvarian tumor-associated antigensDendritic cell-based immunotherapyTumor-specific immune responsesEffective tumor antigensTherapeutic DC vaccinationNovel immunotherapeutic strategiesStandard treatment modalityCell-based immunotherapyOvarian tumor antigenSpecific immune responseTumor-associated antigensPotential of DCDC vaccinationImmunotherapeutic strategiesDendritic cellsCancer vaccinationCancer patientsGynecologic oncologyTreatment modalitiesNatural adjuvantImmune responseAntigen preparationsInduction of tumour-specific CD8+ cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer
Santin AD, Bellone S, Ravaggi A, Roman JJ, Pecorelli S, Parham GP, Cannon MJ. Induction of tumour-specific CD8+ cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer. British Journal Of Cancer 2002, 86: 151-157. PMID: 11857027, PMCID: PMC2746546, DOI: 10.1038/sj.bjc.6600026.Peer-Reviewed Original ResearchConceptsAutologous tumor cellsUterine serous papillary cancerAutologous dendritic cellsT cellsPatient 1Patient 3Tumor cellsDendritic cellsPapillary cancerOvarian cancerAutologous tumor target cellsTumor lysate-pulsed DCsAnti-HLA class IUterine serous papillary carcinomaColor flow cytometric analysisCancer-specific CD8Cisplatinum-based chemotherapyLumboaortic lymph nodesPapillary cancer patientsTumor-specific toleranceTumor-specific CD8Intracellular cytokine expressionHigh-grade ovarian cancerT lymphocyte responsesStrong cytolytic activity
2001
Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.
Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, Jayaprabhu S, Pecorelli S, Parham GP, Cannon MJ. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells. Clinical Cancer Research 2001, 7: 804s-810s. PMID: 11300476.Peer-Reviewed Original ResearchMeSH KeywordsCD56 AntigenCD8-Positive T-LymphocytesCell LineDendritic CellsDNA-Binding ProteinsFemaleFlow CytometryHLA-A2 AntigenHumansImmunotherapyInterferon-gammaMembrane GlycoproteinsOncogene Proteins, ViralPapillomavirus E7 ProteinsPerforinPhenotypePore Forming Cytotoxic ProteinsTime FactorsT-Lymphocytes, CytotoxicTumor Cells, CulturedUterine Cervical NeoplasmsConceptsAntigen-specific CTL responsesE7-specific CD8Dendritic cellsTumor target cellsHPV 16CTL responsesHLA-A2Lymphoblastoid cell linesCD56 expressionTumor cellsHealthy individualsType 1 cytokine profileAnti-HLA class IHLA-A2 monoclonal antibodyAutologous dendritic cellsE7-specific CTLExpression of CD56Subset of CD8Human papillomavirus infectionTarget cellsImportant risk factorHigh cytolytic activityCervical cancer cell linesIntracellular perforin expressionCell linesIntrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma.
Clemons-Miller AR, Chatta GS, Hutchins L, Angtuaco EJ, Ravaggi A, Santin AD, Cannon MJ. Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma. Clinical Cancer Research 2001, 7: 917s-924s. PMID: 11300492.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, NeoplasmB-LymphocytesCD8-Positive T-LymphocytesCytokinesDendritic CellsEnzyme-Linked Immunosorbent AssayFemaleFlow CytometryGp100 Melanoma AntigenHumansImmunotherapyImmunotherapy, AdoptiveIndiumInterferon-gammaInterleukin-2Interleukin-4Interleukin-6MART-1 AntigenMelanomaMembrane GlycoproteinsMeningeal NeoplasmsMiddle AgedMonophenol MonooxygenaseNeoplasm ProteinsProteinsReverse Transcriptase Polymerase Chain ReactionTime FactorsTissue DistributionT-Lymphocytes, CytotoxicTumor Cells, CulturedTumor Necrosis Factor-alphaConceptsTumor necrosis factor alphaNecrosis factor alphaNeurological symptomsLeptomeningeal melanomaFactor alphaLow-dose IL-2 administrationType 1 cytokine profileAutologous dendritic cellsIL-2 administrationRight carotid arteryIntra-arterial deliveryT-cell immunotherapyGreater lytic activityLoss of hearingCTL infusionCytokine profileAutologous EBVDendritic cellsRecurrent melanomaOmmaya reservoirSpecific CTLIL-6IL-4Specific lysisLower extremities